Ботулотоксин типа А в лечении расстройств мочеиспускания у больных рассеянным склерозом
https://doi.org/10.25694/URMJ.2018.09.36
Аннотация
Наиболее распространенным методом лечения нейрогенной детрузорной гиперактивности у больных РС является назначение антихолинергических препаратов, однако действие м-холиноблокаторов часто оказывается недостаточным, либо они плохо переносятся в связи с большим количеством побочных явлений. В обзоре проанализированы данные литературы об эффективности и безопасности использования ботулинического токсина в лечении нейрогенной дисфункции нижних мочевыводящих путей у больных рассеянным склерозом.
Об авторах
Екатерина Сергеевна Филиппова
ФГБОУ ВО Уральский государственный медицинский университет Минздрава России
Россия
Россия
Игорь Владимирович Баженов
ФГБОУ ВО Уральский государственный медицинский университет Минздрава России
Россия
Россия
Список литературы
1. de Seze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B, Groupe The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007;13:915-28.
2. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Disparities in the management of multiple sclerosis-related bladder symptoms. Neurology 2007;68:1971-8.
3. Giannantoni A, Scivoletto G, Di Stasi SM, Grasso MG, Vespasiani G, Castellano V. Urological dysfunctions and upper urinary tract involvement in multiple sclerosis patients. Neurourol Urodyn 1998;17:89-98.
4. Araki I, Matsui M, Ozawa K, Takeda M, Kuno S. Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol 2003;169:1384-7.
5. Hinson JL, Boone TB. Urodynamics and multiple sclerosis. Urol Clin North Am 1996;23:475-81.
6. Fowler CJ, Panicker JN, Drake M, Harris C, Harrison SCW, KirbyM, et al. A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Med J 2009;85:552-9.
7. Nicholas RS, Friede T, Hollis S, Young CA. Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev 2009;1:CD004193.
8. Linsenmeyer TA. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord Med 2013;36:402-19.
9. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 1981;79:734-70.
10. Montecucco C, Rossetto O, Caccin P, Rigoni M, Carli L, Morbiato L, et al. Different mechanisms of inhibition of nerve terminals by botulinum and snake presynaptic neurotoxins. Toxicon 2009;54:561-4.
11. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000;80:718- 50.
12. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006;49:644-50.
13. Аполихин О.И., Чернышев И.В., Абдуллин И.И., Дутикова Е.М., Орлова О.Р., Салюков Р.В., Антонова Л.Е. Лечение нейрогенной детрузорной гиперактивности и детрузорно-сфинктерной диссинергии препаратом Лантокс (Lantox). Эксперимантальная и клиническая урология 2010; 1:97-101.
14. Кривобородов Г.Г, Школьников М.Е. Лечение функциональных нарушений опорожнения мочевого пузыря. Лечащий врач 2004; 9:6-39.
15. Мазо Е.Б., Кривобородов Г.Г., Школьников М.Е., Ефремов Н.С. Применение ботулинического токсина в урологии. Фарматека 2006; 10:125-127.
16. Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C, et al. Efficay and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, doubleblind study. Scand J Urol Nephrol 2007;41:335-40.
17. Del Popolo G, Filocamo MT, Li Marzi V, Macchiarella A, Cecconi F, Lombardi G, et al. Neurogenic detrusor overactivity treated with English botulinum toxin A: 8-year experience of one single centre. Eur Urol 2008;53:1013-20.
18. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005;47:653-9.
19. Bottet F, Peyronnet B, Boissier R, Reiss B, Previnaire JG, Manunta A, Kerdraon J, Ruffion A, Lenormand L, Perrouin Verbe B, Gaillet S, Gamé X, Karsenty G. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed. Neurourol Urodyn. 2018 Jan;37(1):291-297. doi: 10.1002/nau.23291. Epub 2017 Apr 21.
20. Dykstra DD, Pryor J, Goldish G. Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: a case report. Arch Phys Med Rehabil 2003;84:1399-400.
21. Ghei M, Maraj BH, Miller R, Nathan S, O’Sullivan C, Fowler CJ, et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, doubleblind, placebo-controlled, crossover trial. J Urol 2005;174:1873-7 [discussion 7].
22. Hirst GR, Watkins AJ, Guerrero K, Wareham K, Emery SJ, Jones DR, et al. Botulinum toxin B is not an effective treatment of refractory overactive bladder. Urology 2007;69:69-73.
23. Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo-controlled 6-month study. J Urol 2005;174:196-200.
24. Reitz A, Stohrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004;45:510-5.
25. Schulte-Baukloh H, Schobert J, Stolze T, Sturzebecher B, Weiss C, Knispel HH. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn 2006;25:110-5.
26. Kalsi V, Gonzales G, Popat R, Apostolidis A, Elneil S, Dasgupta P, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007;62:452-7.
27. Game X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudie I, De Boissezon X, Malavaud B, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 2008;53:613-8.
28. Deffontaines-Rufin S, Weil M, Verollet D, Peyrat L, Amarenco G. Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients. Int Braz J Urol 2011;37:642-8.
29. Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol 2011;185:2229-35.
30. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxin A in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011;60:742-50.
31. Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012;187:2131-9.
32. Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2013 Nov;32(8):1109-15.
33. Martins-Silva C, Cruz F. Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials. Eur Urol Focus. 2016 Aug;2(3):329-331.
34. Zhang R, Xu Y, Yang S, Liang H, Zhang Y, Liu Y. OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review. Int Braz J Urol. 2015 Mar-Apr;41(2):207-19.
35. Cheng T, Shuang WB, Jia DD, Zhang M, Tong XN, Yang WD et al. Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016 Jul 27;11(7):e0159307.
36. Gaillet S, Bardot P, Bernuz B, Boissier R, Lenne-Aurier K, Thiry-Escudier I, et al. Five years follow-up study and failures analysis of botulinum toxin repeated injections to treat neurogenic detrusor overactivity. Prog Urol 2012;22:1064-70.
37. Reitz A, Denys P, Fermanian C, Schurch B, Comperat E, Chartier-Kastler E. Do repeat intradetrusor botulinum toxin type A injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 2007;52:1729-35.
38. Joussain C, Popoff M, Phé V, Even A, Bosset PO, Pottier S et al. Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity. Neurourol Urodyn. 2018 Feb;37(2):799-806.
39. Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron RL. Botulinum toxin A improves the quality of life in patients with neurogenic urinary incontinence. Eur Urol 2007;52:850-8.
40. Kalsi V, Popat RB, Apostolidis A, Kavia R, Odeyemi IA, Dakin HA, et al. Cost-consequence analysis evaluating the dose of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 2006;49:519 27
41. Khan S, Game X, Kalsi V Gonzales G, Panicker J, Elneil S, et al. Longterm effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol 2011;185:1344 9
42. Chancellor MB, Patel V, Leng WW, Shenot PJ, Lam W, Globe DR et al. Onabotulinumtoxin A improves quality of life in patients with neurogenic detrusor overactivity. Neurology. 2013 Aug 27;81(9):841-8.
43. Gallien P, Reymann JM, Amarenco G, Nicolas B, de Seze M, Bellissant E. Placebo-controlled, randomised, double-blind study of the effects of botulinum A toxin on detrusor-sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 2005;76:1670-6.
44. Bergeron M, Nadeau G, Moore K. The use of urodynamic studies for the followup of neurogenic bladders treated with onabotulinumtoxin A. Can Urol Assoc J. 2018 Feb 23. [Epub ahead of print]
45. Koschorke M, Leitner L, Sadri H, Knüpfer SC, Mehnert U, Kessler TM. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment? BJU Int. 2017 Dec;120(6):848-854.
46. Stamm AW, Adelstein SA, Chen A, Lucioni A, Kobashi KC, Lee UJ. Inconsistency in the definition of urinary tract infection after intravesical botulinum toxin A injection: a systematic review. J Urol. 2018 Apr 10.
47. Manack A, Motsko SP, Haag-Molkenteller C, Dmochowski RR, Goehring Jr EL, Nguyen-Khoa BA, et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn 2011;30:395-401.
48. Harris MA, Harding C, Fulford S, Whiteway J. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment. BJUInt 2011;107:1165 [author reply].
49. Mouttalib S, Khan S, Castel-Lacanal E, Guillotreau J, De Boissezon X, Malavaud B, et al. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment. BJU Int 2010;106:1677-80.
50. Mehnert U, Birzele J, Reuter K, Schurch B. The effect of botulinum toxin type A on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol 2010;184:1011-6.
51. Kaviani A, Khavari R. Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity. Urol Clin North Am. 2017 Aug;44(3):463-474.
52. Chen SF, Jiang YH, Kuo HC. Single onabotulinumtoxinA 200U dose improved clinical symptoms but not urothelial dysfunction in neurogenic detrusor overactivity due to spinal cord injury. J Formos Med Assoc. 2018 Feb 23. pii: S0929-6646(17)30867-7.
Рецензия
Для цитирования:
Филиппова ЕС, Баженов ИВ. Ботулотоксин типа А в лечении расстройств мочеиспускания у больных рассеянным склерозом. Уральский медицинский журнал. 2018;(9):142-150. https://doi.org/10.25694/URMJ.2018.09.36
For citation:
Philippova ES, Bazhenov IV. Botulinum toxin type A for the treatment of low urinary tract dysfunction in patients with multiple sclerosis. Ural Medical Journal. 2018;(9):142-150. (In Russ.) https://doi.org/10.25694/URMJ.2018.09.36
Просмотров:
118
Послать статью по эл. почте 